An open-label 12 month study to evaluate the safety, tolerability and efficacy of OraVescent fentanyl citrate [fentanyl] for the management of breakthrough pain in opioid-tolerant patients with chronic noncancer pain
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2007
At a glance
- Drugs Fentanyl (Primary)
- Indications Pain
- Focus Adverse reactions; Registrational
- Sponsors Cephalon
- 13 Nov 2007 Status changed from in progress to completed.
- 10 Nov 2005 New trial record.